Skip to content
ESPT
MARKETS / NASDAQ / Health care / Biotechnology / FATE
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Fate Therapeutics Inc. FATE

18 fiscal years on record · USD · FY2025 reported · SEC filings only
$6.6M
▼ 51.2% YoY
$-136.3M
$-112.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We have established a proprietary iPSC product platform and have amassed significant internal expertise in the production of off-the-shelf, multiplexed-engineered, T-cell and NK cell product candidates for therapeutic use. Utilizing our iPSC product platform, we are developing off-the-shelf, multiplexed-engineered T-cell and natural killer (NK) cell product candidates which are selectively designed and incorporate novel synthetic controls of cell function to uniquely enhance the therapeutic capacity of the drug product to deliver multiple therapeutic mechanisms to patients. We were incorporated in Delaware in 2007, and are headquartered in San Diego, California. As of December 31, 2025, we employed 161 employees, all of whom are full-time employees, including 27 in research and development, 103 in clinical development, manufacturing and regulatory affairs and 31 in general and administrative.

Written from the business description in FATE THERAPEUTICS INC's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 6.6M
Revenue, FY2025 · full 18-year series below
Revenue $M Net income $M
FY2025 · Revenue 6.6 · Net income -136.3
40M80M-100M-200M
2008201120142017202020232025
Compound annual growth
−59.0%
−26.7%
+10.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −26.7% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -2222.4% · Net ·
-1000%-2000%
200820162025
ROE
FY2025 · ROE -51.8%
-50%
200820162025
Three returns, three denominators.
Gross margin·
Operating margin-2222.4%
Net margin·
EBITDAUSD -134.8M

Each USD of equity lost 52 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -112.0
-100M-200M
200820162025
Net buybacks $ Dividends $
FY2011 · Dividends · · Net buybacks -7000.0
-2500.0-5000.0
2011
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 318.9M
EquityUSD 207.2M
CashUSD 46.6M
Current ratio5.79×

Equity funds 65% of total assets.

The 18-year record

18 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
FATE, 18-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011201020092008
Revenue $B0.00.00.10.10.10.00.00.00.00.00.0◌0.00.00.0◌◌◌
Operating income $B−0.1−0.2−0.2−0.3−0.2−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
EBITDA $B−0.1−0.2−0.2−0.3−0.2−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
Income tax $B0.00.00.00.00.00.00.0◌◌◌◌◌◌◌◌◌◌◌
Net income $B−0.1−0.2−0.2−0.3−0.2−0.2−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.1−0.1−0.1−0.3−0.2−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
EPS, diluted $−1.15−1.64−1.64−2.91−2.24−2.10−1.44−1.19−1.02−1.05−1.18−1.27−3.54−13.06−16.16◌◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————————————
ROE %−51.8−54.2−37.8−48.5−39.9−55.1−48.4−56.0−57.1−60.2−90.4−65.4——————
Shares out B0.120.110.100.100.100.090.080.060.050.040.030.020.020.00◌◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 61 reconciliationsAUDITED

Reconciled in 18 of the 18 fiscal years we could check. 10 checks were skipped: the balance sheet is not tagged before 2012. Four checks were skipped: EPS is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2008

Share this section

Download image